Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2022-02-25 00:00:00 ET · period of report 2022-02-23 · accession 0001209191-22-013281 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-25 | 2022-02-23 | ACAD | Schneyer Mark C. | CFO | M - OptEx | $0.00 | +1,352 | 2,655 | +104% | $0 |
| D | 2022-02-25 | 2022-02-23 | ACAD | Schneyer Mark C. | CFO | S - Sale+OE | $23.80 | -553 | 2,102 | -21% | -$13.2K |
| D | 2022-02-25 | 2022-02-23 | ACAD | Schneyer Mark C. | CFO | M - OptEx | $0.00 | +1,352 | 4,059 | +50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-23 | M | A | 1,352 | $0.00 | 2,655 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-23 | S | D | 553 | $23.80 | 2,102 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2022-02-23 | M | A | 1,352 | $0.00 | 4,059 | D | — · — to — | 1,352 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning February 23 2022. |